Massachusetts-based startup EIP Pharma has presented data on its sole candidate neflamapimod at AAIC 2017, the Alzheimer’s Association International Conference, 18 July 2017
As a lifelong follower of the so-called ‘tau hypothesis’, TauRx Therapeutics chief executive Claude Wischik ploughed a lonely furrow for many years. 18 July 2017
The American biotech firm Alzheon has unveiled data being presented at the Alzheimer’s Association International Conference (AAIC), in London. 17 July 2017
A study conducted at New York University has shown that combining memantine hydrochloride with a care management program can multiply the improvement on daily f 17 July 2017
Massachusetts-based Biogen has provided a preview of the data it will present at the Alzheimer’s Association International Conference, the pre-eminent Alzheimer 14 July 2017
Ahead of next week’s Alzheimer’s Association International Conference in London, Eli Lilly has published a curtain raiser outlining the more than 40 abstracts t 13 July 2017
Isodiol International (CSE: ISOL), a specialist in cannabis-derived pharmaceuticals, has received approval from the Brazilian medicines regulator to market Isod 10 July 2017
A consensus review has been published on the efficacy of cannabinoids as medical drugs and comparing them with other forms of cannabis treatments with herbal pl 7 July 2017
Failed drug trials have led to questions about whether the amyloid hypothesis, the leading theory on the cause of Alzheimer’s disease, might be wrong. 15 June 2017
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.